Lithium ACE inhibitors, NSAIDs, and verapamil. A possible fatal combination.
Department of Psychiatry and Behavioral Sciences, State University of New York at Stony Brook, USA.
S S
SS
Chandragiri
E
E
Pasol
R M
RM
Gallagher
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D018692:Antimanic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D015897:Comorbidity; D004347:Drug Interactions; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D017706:Lisinopril / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D016651:Lithium Carbonate / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D012307:Risk Factors; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018692:Antimanic Agents; D002121:Calcium Channel Blockers; D016651:Lithium Carbonate; D014700:Verapamil; D017706:Lisinopril; D001241:Aspirin